Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 26, 2009

Center for Translational Pathology Purchases Genomatix’ Next-Gen Sequencing Analysis Systems

  • The Center for Translational Pathology at the University of Michigan installed a Genomatix Mining Station (GMS) and a Genomatix Genome Analyzer (GGA) at its labs in Ann Arbor, MI. The two technologies work in conjunction to provide an analysis of next-generation sequencing data.

    GMS is based on a genomic pattern recognition paradigm, or GenomeThesaurus, which allows for input of raw sequence reads plus optional quality files from any sequencing hardware. GGA delivers downstream software tools and databases for the analysis of GMS data.

    GMS reportedly provides ultrafast mapping of sequences of any length (starting from 8 bp) with no practical limits on the number of point mutations and/or insertions and deletions that can be taken into account during the mapping process. Depending on the nature of the experiment, the GMS can provide SNP detection and genotyping, copy number analysis, and small RNA analysis.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »